Supernus Pharmaceuticals, Inc. (SUPN)

Supernus Pharmaceuticals Revenue

Supernus Pharmaceuticals had revenue of $597.40M in the twelve months ending March 31, 2024, down -10.64% year-over-year. Revenue in the quarter ending March 31, 2024 was $143.64M, a -6.58% decrease year-over-year. In the year 2023, Supernus Pharmaceuticals had annual revenue of $607.52M, a decrease of -8.95%.

• Revenue (ttm): $597.40M
• Revenue Growth: -10.64%
• P/S Ratio: 2.37
• Revenue / Employee: $916,259
• Employees: 652
• Market Cap: 1.42B USD

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2023	607.52M	-59.72M	-8.95%
Dec 31, 2022	667.24M	87.46M	15.09%
Dec 31, 2021	579.78M	59.38M	11.41%
Dec 31, 2020	520.40M	127.64M	32.50%
Dec 31, 2019	392.76M	-16.14M	-3.95%
Dec 31, 2018	408.90M	106.66M	35.29%
Dec 31, 2017	302.24M	87.24M	40.57%
Dec 31, 2016	215.00M	67.54M	45.80%
Dec 31, 2015	147.47M	54.79M	59.12%
Dec 31, 2014	92.68M	80.66M	671.10%
Dec 31, 2013	12.02M	10.54M	712.09%
Dec 31, 2012	1.48M	677.00K	84.31%
Dec 31, 2011	803.00K	697.00K	657.55%
Dec 31, 2010	106.00K	-37.82M	-99.72%
Dec 31, 2009	37.93M	-	-

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.